Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Skin Cancer Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

Dermato-Onco2024 | Real-time surveillance with ctDNA in stage III BRAF-positive melanoma

Gabriele Roccuzzo, MD, University of Turin, Turin, Italy, shares results from a longitudinal study, which explored the predictive accuracy of circulating tumor DNA (ctDNA) for relapse risk in patients with stage III BRAF-positive cutaneous melanoma. The cohort consisted of 32 patients who received either immunotherapy or targeted therapy in adjuvant settings. A 12-month follow-up revealed that patients who expressed higher levels of ctDNA were correlated to a higher risk of relapse. This interview took place at The European Congress on Dermato-Oncology 2024 in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.